معرفی
Dr. Jonathan Izawa is an Associate Professor in the Department of Surgery at Western University's Schulich School of Medicine and Dentistry, with additional appointments at London Health Sciences Centre, Lawson Health Research Institute, and McGill University. He is a prominent urologic oncologist specializing in prostate and bladder cancer research.
His research interests focus on active surveillance protocols for low-risk prostate cancer, clinical trials investigating metformin's role in prostate cancer management, and comparative effectiveness of surgical approaches for bladder cancer. Dr. Izawa has made significant contributions to understanding optimal radiation therapy techniques for muscle-invasive bladder cancer and the impact of histologic subtypes on treatment outcomes.
Analysis of his recent publications reveals a strong emphasis on methodologically rigorous clinical research, with numerous randomized controlled trials, multi-institutional database analyses, and sophisticated statistical approaches including inverse probability treatment weighting. His work consistently addresses clinically relevant questions that directly impact patient management decisions in urologic oncology.
Dr. Izawa maintains active collaborations across Canadian academic centers through the Canadian Bladder Cancer Information System (CBCIS), which includes 14 academic institutions. His research has been published in high-impact journals including the Journal of Clinical Oncology, JAMA SURGERY, and The Journal of Urology.
His clinical trial work, particularly the Metformin Active Surveillance Trial (MAST), represents a significant contribution to the field of prostate cancer management. His research on radical cystectomy outcomes, pelvic lymph node dissection, and radiation therapy techniques continues to inform contemporary urologic oncology practice guidelines in Canada and internationally.
